Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, NKGen Biotech Inc (NASDAQ: NKGN) closed at $0.57 up 2.23% from its previous closing price of $0.56. In other words, the price has increased by $2.23 from its previous closing price. On the day, 0.21 million shares were traded. NKGN stock price reached its highest trading level at $0.6 during the session, while it also had its lowest trading level at $0.5508.
Ratios:
For a deeper understanding of NKGen Biotech Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.02 and its Current Ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKGN now has a Market Capitalization of 20244974 and an Enterprise Value of 48257960.
Stock Price History:
The Beta on a monthly basis for NKGN is 0.53, which has changed by -0.786194 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, NKGN has reached a high of $4.06, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 28.45%, while the 200-Day Moving Average is calculated to be -37.04%.
Shares Statistics:
For the past three months, NKGN has traded an average of 1.40M shares per day and 489680 over the past ten days. A total of 25.77M shares are outstanding, with a floating share count of 18.56M. Insiders hold about 47.76% of the company’s shares, while institutions hold 10.57% stake in the company. Shares short for NKGN as of 1734048000 were 722225 with a Short Ratio of 0.52, compared to 1731628800 on 691794. Therefore, it implies a Short% of Shares Outstanding of 722225 and a Short% of Float of 7.19.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
